Bimekizumab Safety and Efficacy in Patients with Psoriatic Arthritis: 3-Year Results from a Phase 2b Open-Label Extension Study

被引：0
|
作者：
Coates, L. C. [1 ]
Warren, R. B. [2 ]
Ritchlin, C. T. [3 ]
Gossec, L. [4 ,5 ]
Merola, J. F. [6 ]
Assudani, D. [7 ]
Coarse, J. [8 ]
Eells, J. [7 ]
Ink, B. [7 ]
McInnes, I. B. [9 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Univ Manchester, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[3] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
[4] Sorbonne Univ, Paris, France
[5] Hop La Pitie Salpetriere, Paris, France
[6] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[7] UCB Pharma, Slough, Berks, England
[8] UCB Pharma, Raleigh, NC USA
[9] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
SWISS MEDICAL WEEKLY | 2021年 / 151卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 18
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2B OPEN-LABEL EXTENSION STUDY
    Coates, L. C.
    Warren, R. B.
    Ritchlin, C. T.
    Gossec, L.
    Merola, J. F.
    Assudani, D.
    Coarse, J.
    Eells, J.
    Ink, B.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 779 - 780
  • [2] Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study
    Mease, Philip
    Deodhar, Atul
    Merola, Joseph
    McInnes, Iain
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Ink, Barbara
    Schett, Georg
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2782 - 2785
  • [3] EFFICACY AND SAFETY OF 108 WEEKS' BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
    Mcinnes, I.
    Merola, J. F.
    Mease, P. J.
    Coates, L. C.
    Joshi, P.
    Coarse, J.
    Ink, B.
    Ritchlin, C. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1149 - 1150
  • [4] Efficacy and Safety of 108 Weeks of Bimekizumab Treatment in Patients with Psoriatic Arthritis: Interim Results from a Phase 2 Open-Label Extension Study
    McInnes, I. B.
    Merola, J. F.
    Mease, P. J.
    Coates, L. C.
    Schmitz, N.
    Joshi, P.
    Coarse, J.
    Ink, B.
    Ritchlin, C. T.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 8S
  • [5] Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
    Merola, Joseph
    Behrens, Frank
    Kivitz, Alan
    Mease, Philip
    McInnes, Iain
    Ink, Barbara
    Assudani, Deepak
    Joshi, Paulatsya
    Coarse, Jason
    Ritchlin, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: ACHIEVEMENT AND MAINTENANCE OF PSORIATIC ARTHRITIS RESPONSE CRITERIA RESPONSES THROUGH 3 YEARS IN A PHASE 2B OPEN-LABEL EXTENSION STUDY
    Tillett, William
    McInnes, Iain B.
    McGonagle, Dennis
    Jadon, Deepak R.
    Ink, Barbara
    Assudani, Deepak
    Coarse, Jason
    Eells, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2022, 61 : I20 - I20
  • [7] Sustained Improvement in Physical Function, Disease Impact and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study
    Gossec, Laure
    Asahina, Akihiko
    Gottlieb, Alice
    Coates, Laura
    Ink, Barbara
    Assudani, Deepak
    Coarse, Jason
    Hellot, Scarlett
    Eells, Jason
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2814 - 2818
  • [8] Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study
    Coates, Laura C.
    McInnes, Iain B.
    Merola, Joseph F.
    Warren, Richard B.
    Kavanaugh, Arthur
    Gottlieb, Alice B.
    Gossec, Laure
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Ink, Barbara
    Ritchlin, Christopher T.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (12) : 1959 - 1970
  • [9] Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension
    Deodhar, Atul
    Navarro-Compan, Victoria
    Poddubnyy, Denis
    Gensler, Lianne
    Ramiro, Sofia
    Tomita, Tetsuya
    Marzo-Ortega, Helena
    Fleurinck, Carmen
    Vaux, Thomas
    Massow, Ute
    van der Heijde, Desiree
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1014 - 1017
  • [10] BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
    Van der Heijde, D.
    Deodhar, A.
    Gensler, L. S.
    Poddubnyy, D.
    Kivitz, A.
    Dougados, M.
    De Peyrecave, N.
    Oortgiesen, M.
    Vaux, T.
    Fleurinck, C.
    Baraliakos, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 332 - 333
12345